Brown Advisory’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Brown Advisory’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$252K	–	1262
2021 Q4	$252K	Sell	3,000 -2,000	-40%	-$155K	﹤0.01%	1096
2021 Q3	$333K	Sell	5,000 -2,000	-29%	-$115K	﹤0.01%	917
2021 Q2	$372K	Sell	7,000 -500	-7%	-$26.8K	﹤0.01%	902
2021 Q1	$325K	Sell	7,500 -458	-6%	-$19.7K	﹤0.01%	932
2020 Q4	$413K	Buy	+7,958	New	+$359K	﹤0.01%	817

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Brown Advisory's ZNTL Position: Q1 2022 in Review

Brown Advisory sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 3,000 shares — an estimated $252K sold.

Brown Advisory first reported a position in ZNTL in Q4 2020 and held it in 5 quarters. The position peaked at $413K in Q4 2020. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

Brown Advisory reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Brown Advisory sold 3,000 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $252K.
Brown Advisory first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Brown Advisory's Zentalis Pharmaceuticals position peaked at $413K in Q4 2020.
128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.